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Protocol
AbstrACt
Introduction Achilles tendinopathy (AT) is a cause of 
pain and disability affecting both athletes and sedentary 
individuals. More than 150 000 people in the UK every 
year suffer from AT. While there is much preclinical work 
on the use of stem cells in tendon pathology, there is a 
scarcity of clinical data looking at the use of mesenchymal 
stem cells to treat tendon disease and there does not 
appear to be any studies of the use of autologous cultured 
mesenchymal stem cells (MSCs) for AT. Our hypothesis is 
that autologous culture expanded MSCs implanted into 
an area of mid-portion AT will lead to improved pain-free 
mechanical function. The current paper presents the 
protocol for a phase IIa clinical study.
Methods and analysis The presented protocol is for a 
non-commercial, single-arm, open-label, phase IIa proof-
of-concept study. The study will recruit 10 participants and 
will follow them up for 6 months. Included will be patients 
aged 18–70 years with chronic mid-portion AT who have 
failed at least 6 months of non-operative management. 
Participants will have a bone marrow aspirate collected 
from the posterior iliac crest under either local or general 
anaesthetic. MSCs will be isolated and expanded from 
the bone marrow. Four to 6 weeks after the harvest, 
participants will undergo implantation of the culture 
expanded MSCs under local anaesthetic and ultrasound 
guidance. The primary outcome will be safety as defined 
by the incidence rate of serious adverse reaction. The 
secondary outcomes will be efficacy as measured by 
patient-reported outcome measures and radiological 
outcome using ultrasound techniques.
Ethics and dissemination The protocol has been 
approved by the National Research Ethics Service 
Committee (London, Harrow; reference 13/LO/1670). 
Trial findings will be disseminated through peer-reviewed 
publications and conference presentations.
trial registration number NCT02064062.
IntroduCtIon 
The Achilles tendon is the largest tendon in 
the body and it plays an important role in 
the biomechanics of the lower extremity. It 
can withstand great forces, especially during 
sporting exercise. The general population has 
an incidence of 2.35 per 1000 people, equiva-
lent to >150 000 people in the UK every year.1 
This is a degenerative process that leads to 
pain and dysfunction in middle-aged individ-
uals and sports participants.2 Tendinopathic 
tendons lose their shiny appearance and 
microscopy reveals discontinuous and disor-
ganised collagen fibres. This is associated 
with mucoid and lipoid degeneration and an 
increasing number of cells within the tendon 
tissue, mostly with a fibroblastic or myofibro-
blastic appearance. Often, there is an abrupt 
discontinuity of both vascular and myofibro-
blastic proliferation immediately adjacent to 
the area of greatest abnormality.3
Achilles tendon degeneration is evident as 
an increased signal on MRI4 and as hypoecho-
genic regions on ultrasound investigation.5 
These areas of abnormal imaging corre-
spond with areas of altered collagen fibre 
structure and increased interfibrillar ground 
substance, which has been shown to consist of 
hydrophilic glycosaminoglycans.4
Achilles tendinopathy (AT) adversely 
affect quality of life by causing chronic pain 
and disability.6 The source of pain has been 
associated with neurovascular ingrowth and 
autocrine/paracrine effect of cellular prod-
ucts (eg, catecholamines, acetylcholine, 
strengths and limitations of this study
 ► A first-in-man safety study.
 ► First study of its kind injecting culture expanded 
mesenchymal stem cells into mid-portion Achilles 
tendinopathy.
 ► Capturing both clinical scores and radiological 
outcomes.
 ► Independent assessment using ultrasound tissue 
characteristics.
 ► Proof-of-concept safety study; therefore, further re-
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glutamate) and a reduction in pain is a key indicator of 
treatment success.3
Numerous management strategies exist for AT, such 
as rest, physiotherapy with eccentric strengthening exer-
cises,7 extracorporeal shockwave therapy,8 dry needling,8 
high-volume injections8 and platelet-rich plasma (PRP) 
injections.9 However, apart from eccentric loading exer-
cises none of these therapies has been shown to be more 
effective than placebo.8 8
The use of PRP is controversial. One randomised 
controlled trial (RCT) looked at PRP versus stromal 
vascular fraction (SVF) derived from adipose. SVF has 
been shown to be source of MSCs. They showed that 
the use of PRP and SVF was safe and that both PRP and 
SVF improved clinical scores with statistical significance. 
The use of SVF seemed to provide quicker improvement 
but at 180 days there was no difference between the two 
groups.10 Another RCT demonstrated that the use of PRP 
had no statistically significant advantage over a saline 
placebo group.9 11
Although the majority of tendon conditions are treated 
non-operatively, up to 45% of patients at some stage 
consider surgery.3 Tendon disorders are a major burden 
on the National Health Service (NHS). A total of 51 454 
operations on tendon disorders were performed in the 
NHS in 2015/2016 (HESOnline), which is up from 
48 765 operations performed in 2004/2005. Given that 
the majority of tendon problems are treated non-opera-
tively, this high surgical caseload represents just the tip of 
the iceberg of the real cost to the health service of tendon 
disease. There is therefore a need for safe and effective 
non-surgical treatments.
Laboratory-based studies looking at autologous mesen-
chymal stem cells (MSCs) injections into damaged 
tendons have shown improved functional and histological 
outcomes.12–15 Smith et al published an equine case-con-
trol trial comparing autologous bone marrow-derived 
MSCs and saline injections. The treated tendons exhib-
ited statistically significant improvements in key parame-
ters with normalisation of biomechanical, morphological 
and compositional parameters.16 Another study followed 
up 141 horses postintralesional MSC injection for digital 
flexor tendinopathy. Two-year follow-up showed no 
adverse effects of the treatment with no aberrant tissue 
on histological examination. The re-injury percentage 
was significantly less than published for national hunt 
racehorses treated in other ways.14
Human studies using MSCs have shown promise in 
many conditions including heart disease,17 musculoskel-
etal disorders,18 autoimmune diseases19 and neurological 
disorders.20
With regard to the use of MSCs in human tendons, 
there are only a handful of reports.
Ellera Gomes et al21 performed a cohort study in 14 
patients who received bone marrow concentrate (BMC) 
derived from the iliac crest with rotator cuff repair. Twelve 
months following the procedure, all patients had better 
clinical scores and MRI showed that tendons had healed.
Hernigou et al22 performed a comparative study looking 
at effect of BMC cells on rotator cuff healing postar-
throscopic repair. Patients treated with BMC had a signifi-
cantly increased healing rate and a significant reduction 
in rerupture. In contrast, Mazzocca et al23 used BMCs 
from the humeral head with a similar model of rotator 
cuff repair, and showed no statistical difference in clinical 
outcome at a mean of 10.6 months.
Pascual-Garrido et al24 looked at eight patients with 
patella tendinopathy. BMCs from the iliac crest were 
injected into the patella tendon under ultrasound guid-
ance. At a mean follow-up of 5 years, there was significant 
improvement in most clinical scores. This improvement 
was seen up to year 2 after which it plateaued. Ultrasound 
evaluation was at 6 months, which showed that eight of 
the nine patients had improvement in the grading of the 
patella tendinopathy.
Singh et al25 looked at 30 patients with untreated tennis 
elbow. BMCs from iliac crest were injected into the lateral 
epicondyle. There was a statistically significant improve-
ment in the patient-rated tennis elbow evaluation score 
at 12 weeks.
All of these studies used mononuclear cells from bone 
marrow concentrate. Usuelli et al published a study 
looking at PRP and SVF. The study concluded that SVF 
was safe and as efficacious as PRP at 180 days, although 
this study did not use culture expanded MSCs.10 We could 
only identify one study looking at culture expanded MSCs 
in AT. Ilić et al reported the use of human placenta-de-
rived allogenic MSCs injected under ultrasound guid-
ance in six patients. They monitored for the primary 
outcome, which was safety. They concluded it was safe 
to inject human placenta-derived MSCs into human 
Achilles tendons, however made no comment on clinical 
outcome.26
There is clearly a lack of reliable evidence for the use 
of MSCs in tendon disease. Our hypothesis is that autol-
ogous culture expanded MSCs implanted into a tendon 
with AT will lead to improvement in pain-free mechan-
ical function. The current paper presents the protocol for 
phase IIa trial to explore this.
MEthods And AnAlysIs
study design
Following dialogue and engagement with the Medicines 
and Healthcare Regulatory Agency (MHRA), the trial 
was defined as a non-commercial, single-arm, open-
label, phase IIa proof-of-concept study. The study will be 
conducted at the Royal National Orthopaedic Hospital 
(RNOH). The study will recruit 10 participants and will 
follow them up for 6 months (figure 1). The MHRA 
considered this study to be a first-in-man (phase IIa) 
study whose primary role was to demonstrate safety and 
hence all patients were to get the active treatment and no 
control group was used. The information from this study 
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The primary outcome will be safety as defined by the 
incidence rate of serious adverse reaction (SAR). The 
secondary outcomes will be efficacy as measured by 
patient-reported outcome measures. Ultrasound tech-
niques will assess the radiological outcome of the proce-
dure. Computerised ‘ultrasound tissue characterisation’ 
(UTC) is also carried out in order to add in a less subjec-
tive assessment. UTC involves a precision instrument that 
moves the ultrasound probe automatically across the long 
axis of the Achilles tendon collecting transverse images 
at even distances of 0.2 mm over a length of 12 cm and 
enable tomographic visualisation and tissue characterisa-
tion and quantification of architecture and integrity of 
the collagenous matrix.
Ultrasound examinations undertaken in this study will 
performed by a musculoskeletal radiologist with expe-
rience of undertaking such an examinations. The end 
of the Autologous Stem Cells in Achilles Tendinopathy 
(ASCAT) trial is the last visit of the last participant.
Inclusion criteria
Patients aged 18–70 years (both males and females) with 
chronic mid-portion AT (defined by pain and tender 
swelling in mid-portion of AT, >1 cm proximal to the 
insertion), with symptoms for longer than 6 months who 
have failed conservative treatment (at least a full course of 
physiotherapy) and for whom surgery is being considered. 
All participants must be able to provide written informed 
consent. Females of childbearing age and potential must 
be willing to use two forms of effective contraception from 
the time of consent to 6 months postinjection (box 1).
recruitment and consent
Patients who are referred to the RNOH will be identified 
as potentially eligible for the trial by the Chief Investigator 
Figure 1 Trial flow diagram. AT, Achilles tendinopathy; EQ-5D-5L, EuroQol 5-dimension 5-level; GMP, good medical practice; 
MOXFQ, Manchester Oxford Foot and Ankle Questionnaire; NHS, National Health Service; SAS, Sporting Activity Score; 
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(CI) or delegated clinician and invited to participate. The 
RNOH is a tertiary referral centre for AT and potential 
participants will be referred by letter to the Foot and 
Ankle Department at the RNOH. The CI or delegated 
clinicians at the Foot and Ankle Department will review 
referral letters. In the main, it may not be possible to 
identify relevant patients with chronic mid-portion AT 
from the referral letters; however, Patient Information 
Sheets may be sent by post or email to referred patients 
informing them of the trial. The CI or delegate will wait 
until the patient is seen in the initial outpatient consul-
tation to explain the trial in more detail and if they are 
eligible invite them to participate. Participant Identifica-
tion Centres (PIC) will also be used to identify potential 
patients for the trial and these may include primary care 
musculoskeletal triage services. Potential participants will 
be referred by the PIC to the trial site.
screening assessments
Prescreening interview will include a medical history 
with discussion about willingness to participate in the 
trial. This will be followed by a clinical assessment that 
will include a routine examination of the foot and ankle, 
including: inspection of limb alignment and other biome-
chanical abnormality such as flat or high arched feet; 
size and location of swelling over the Achilles tendon 
and range of motion of the ankles, hindfeet, midfeet 
and forefeet. Assessment of gastrocnemius tightness will 
be performed with the knee fully straight and flexed 20 
degrees (Silfverskiold test). Examination will aim to rule 
out other conditions such as an adjacent bursitis or inser-
tional tendinopathy (tenderness over the calcaneal bony 
attachment). The Simmonds’ test will be performed to 
ensure continuity of the tendon.
Blood tests will be performed to ensure compliance 
with the Human Tissue (Quality and Safety for Human 
Application) Regulations 2007 and local procedures. The 
minimum blood tests required as specified by the regu-
lations will be hepatitis B virus, hepatitis C virus, HIV-1 
and HIV-2, syphilis and human T-cell lymphotropic virus. 
These tests will be carried out at least 1 week before 
(and within 30 days of the bone marrow harvest proce-
dure) in line with the regulations. Additionally, a preg-
nancy test will be carried out prior to the bone marrow 
harvest (within 1 week), if the participant is a female of 
childbearing age and potential. If any of these tests are 
positive, the participant will be counselled and deemed 
ineligible for the trial.
baseline assessment
Baseline assessments to be carried out on day 0, immedi-
ately prior to harvest include:
 ► Clinical assessment;
 ► Baseline questionnaire on demographics and comor-
bidity/concomitant medication;
 ► Victorian Institute of Sports Assessment Achilles 
(VISA-A) Questionnaire;
 ► Visual Analogue Score (VAS);
 ► Manchester Oxford Foot and Ankle Questionnaire 
(MOXFQ);
 ► EuroQol 5-dimension 5-level (EQ-5D-5L) Question-
naire;
 ► Sporting Activity Score (SAS);
 ► Ultrasound imaging and UTC;
 ► Adverts events (AE) review.
Table 1 shows all the planned assessments and proce-
dures that will be performed before MSC implantation.
treatment procedure
For eligible participants, approximately 8 mL of bone 
marrow aspirate will be collected from the posterior iliac 
crest into a heparinised syringe under either local or 
general anaesthetic. A decision on which technique will 
be used will depend on discussions with the patient. MSC 
processing and manufacturing will be at the cell-pro-
cessing centre at the Centre for Cell Gene and Tissue 
Therapeutics based at the Royal Free Hospital in London. 
The cells are cultured using a standardised protocol using 
fetal calf serum in the culture medium with robust vali-
dation systems to confirm quality and sterility of cells. 
Approximately 5 weeks after bone marrow harvest, partic-
ipants will undergo implantation of the culture expanded 
MSCs under local anaesthetic in the outpatient setting 
following clinical assessment and tendon imaging using 
conventional ultrasound and UTC measurement.27
A single injection of between 4 and 20×106 MSCs 
suspended in 1 mL of Dulbecco’s Modified Eagle Medium 
box 1 Inclusion and exclusion criteria for the study
Inclusion criteria:
1. Aged ≥18 and ≤70 years (both males and females).
2. Participants with chronic mid-portion Achilles tendinopathy (AT) (as 
defined by pain in region of AT and tender swelling in mid-portion 
of the AT with symptoms for longer than 6 months who have failed 
conservative treatment (at least a full course of physiotherapy) and 
for whom surgery is being considered.
3. Able to provide written informed consent.
4. Females of childbearing age and potential must be willing to use 
two forms of effective contraception from the time of consent to 
6 months postinjection.
Exclusion criteria:
1. Previous bony surgery (eg, reconstructive pelvic osteotomy) at or in 
proximity to the bone marrow harvest site.
2. Pregnancy or lactation (self-declaration at screening visit with fol-
low-up urine pregnancy test to be confirmed not beyond 7 days prior 
to mesenchymal stem cell (MSC) harvest and administration).
3. Current use of steroids, antitumour necrosis factor drugs, metho-
trexate or ciprofloxacin (or use within 4 weeks of assessment for 
eligibility).
4. Positive for hepatitis B virus, hepatitis C  virus , HIV-1 and HIV-2, 
syphilis and human T-cell lymphotropic virus.
5. Previous AT surgery on the tendon to receive MSC implantation.
6. Inflammatory arthritis.
7. Known or suspected underlying haematological malignancy.
8. Other active malignancy in the past 3 years.
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will be injected under ultrasound control by a delegated, 
experienced and trained radiologist along the length of 
the tendon at the area of greatest degeneration starting 
just distal to the degeneration and finishing just proximal 
to normal structure. Participants will be observed for a 
minimum of 2 hours after implantation for any imme-
diate adverse effects.
All participants will be referred for a standard course of 
physiotherapy. The physiotherapist will issue a discharge 
summary following their treatment and a copy of this 
will be included in the participant record. This summary 
includes details on participant compliance.
subsequent assessments
Subsequent assessments following the MSC implanta-
tion include AE review, VAS (pain) , MOXFQ, VISA-A 
Questionnaire, EQ-5D, SAS Questionnaire, ultrasound 
imaging (conventional ultrasound and UTC) and clin-
ical assessment (table 1). These will occur at 6, 12 and 
24 weeks post-MSC implantation. After 2 days, the trial 













Day 0 Day 2† Week 6 Week 12 Week 24
Deviation window 
(days)
‡ ±14 0 0 hours ±7 ±7 ±7
Eligibility review X X
Medical history X
Informed consent X
Clinical assessment X X
HBV, HCV, HIV-1 and 
HIV-2 and syphilis 
tests
X
Pregnancy tests X§ X X¶ 
Bone marrow harvest X
MSC implantation X






X** X†† X†† X††
VISA-A Questionnaire X X X X
VAS X X X X
MOXFQ X X X X
EQ-5D Questionnaire X X X X
SAS Questionnaire X X
Concomitant 
medication
X X X X X X X X
AE review X X X X X X X
*Urine pregnancy test at bone marrow harvest.
†Day 2 follow-up assessments are done by telephone.
‡Screening procedures must take place at least 1 week before and within 30 days of the bone marrow procedure.
§Self-declaration from the patient.
¶Within 7 days of implantation.
**The number of visits are dependent on participant’s progress and are not obligatory at these time points. Standard NHS protocol for 
physiotherapy will start within 1–2 weeks after implantation. Dates of physiotherapy attendances will be recorded in the case report form.
††Two radiologists will independently scan the participant using ultrasound. UTC will also be measured twice on each occasion.
AE, adverse events; EQ-5D-5L, EuroQol 5-dimension 5-level; HBV, hepatitis B virus; HCV, hepatitis C virus; MOXFQ, Manchester Oxford Foot 
and Ankle Questionnaire; SAS, Sporting Activity Score; UTC, ultrasound tissue characteristics; VAS, Visual Analogue Score; VISA-A, Victorian 
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coordinator will phone the patient to check they are well 
and record any AEs on the ASCAT case report form. The 
trial will end on the last visit of the last precipitant.
Patient and public involvement
Patients and the public were not directly involved with 
the development of the current protocol. The primary 
research question is the safety of use of culture expanded 
MSCs. This will enable the development of a larger RCT 
that will involve oversight from the patient and public 
representatives. Patient recruitment is described above 
and the results will be disseminated to the participants via 
a news letter.
Power and sample size
Sample size was determined to ensure a predetermined 
level of accuracy for the incidence of SAR using an exact 
binomial CI. With 10 participants, if no SAR is observed 
we can rule out a true SAR rate of 31% or greater with 
95% confidence, or a true SAR rate of 21% or greater 
with 80% confidence, or a true SAR rate of 13% or 
greater with 50% confidence. With six participants for the 
interim analysis, if no SAR is observed we can rule out a 
true SAR rate of 46% or greater with 95% confidence, or 
a true SAR rate of 32% or greater with 80% confidence, 
or a true SAR rate of 21% or greater with 50% confi-
dence. Since the study is a proof-of-concept pilot study, 
no formal power calculation was performed.
statistical analysis
The findings from this study will be published and the 
data will also be included in subsequent larger trials if 
appropriate. Baseline data collected and summarised 
will include: participant gender, age, height, weight, 
body mass index, duration of symptoms, sporting activity, 
smoking/non-smoking, medication, any other muscu-
loskeletal problems, EQ-5D, MOXFQ, VAS (pain), SAS 
score, VISA-A score and ultrasound findings (conven-
tional ultrasound and UTC findings).
Continuous baseline data will be presented as mean 
and SD for normally distributed variables, medians and 
IQRs for non-normally distributed variables and frequen-
cies and percentages for categorical baseline variables. 
For the primary outcome, the proportion of participants 
experiencing a SAR at any time over the 24-week follow-up 
period will be calculated along with exact binomial CIs to 
express the uncertainty in the observed incidence rate of 
SAR.
Since the primary outcome is the incidence of SARs, 
missing outcomes are not anticipated. The primary anal-
ysis will be as per-protocol. All participants will receive 
the same treatment, which cannot be withdrawn once 
given and we will only analyse the data from the partici-
pants who actually receive autologous culture expanded 
MSCs. Cancellation of implantation will be a logistical 
rather than surgical decision and as such is not expected 
to introduce bias. The proportion of participants expe-
riencing a success at 6 months will be calculated along 
with exact binomial CIs to express the uncertainty in the 
observed incidence of success at 6 months. Changes from 
baseline in EQ-5D, MOXFQ, VAS (pain), VISA-A and SAS 
scores will be summarised as mean and SD if normally 
distributed, or median and IQR if the data do not demon-
strate normality.
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